A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Exclusion Criteria

• •Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 3 months after the final dose of tocilizumab, 2 months after the final dose of glofitamab, whichever is longer
• •Leukemic, non-nodal MCL
• •History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
• •Contraindication to obinutuzumab or rituximab, and either bendamustine or lenalidomide
• •Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3
• •Prior treatment with CAR-T cell therapy
• •Treatment with systemic therapy or BTK inhibitors, or any investigational agent for the purposes of treating cancer within 2 weeks or 5 half-lives (whichever is shorter) prior to first study treatment
• •Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma
• •Current or history of CNS disease, such as stroke, epilepisy, CNS vasculitis, or neurodegenerative disease
• •History of other malignancy that could affect compliance with the protocol or interpretation of results
• •Significant or extensive cardiovascular disease
• •Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment or any major episode of infection within 4 weeks prior to the first study treatment
• •Suspected or latent tuberculosis
• •Positive test for hepatitis B virus (HBV) or hepatitis C virus (HCV)
• •Known or suspected chronic active Epstein-Barr viral infection (EBV)
• •Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
• •Known history of progressive multifocal leukoencephalopathy (PML)
• •Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better
• •Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study
• •Prior solid organ transplantation or allogenic stem cell transplant
• •Eligibility for stem cell transplantation (SCT)
• •Active autoimmune disease requiring treatment
• •Prior treatment with systemic immunosuppressive medications within 2 weeks or five half-lives (whichever is shorter) prior to the first dose of study treatment
• •Corticosteroid therapy within 2 weeks prior to first dose of study treatment
• •Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis
• •Clinically significant history of cirrhotic liver disease